Certara, Inc. · NASDAQ:CERT

Certara — Blueprint for Biotech Success webinar (September 2025)

27 slides from Certara's conference presentation, September 2025

  1. Slide 1: Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value

    Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value

  2. Slide 2: Webinar speakers

    Webinar speakers Kevin Hershberger, BPharm, MBA Colin Callaghan, BPharm, MBA Max Vargas, PhD, MBA Vice President Nonclinical Senior Director, Program Leadership Vice President, Evidence & Access Development Sciences Certara Strategy Certara Certara

  3. Slide 3: Agenda topics

    Agenda topics • Laying the Foundation for Early Development Success • Commercial Considerations for Early Development – Setting the Destination • Securing Biotech Investment: Strategies for Success © Copyright 2025 Certara, Inc. All rights reserved. 3

  4. Slide 4: Laying the Foundation for Early Development Success

    Laying the Foundation for Early Development Success Kevin Hershberger, BPharm, MBA Vice President Nonclinical Development Sciences Certara Drug Development Solutions 4

  5. Slide 5: The Value of Better Decisions

    The Value of Better Decisions High attrition rates, lengthy development timelines, ballooning costs continue to plague the industry. Optimizing early development plans with drug development and biosimulation experts can mitigate these program risks. Number of Drug Phase Failure Rate % Dev Cost Cost

  6. Slide 6: Potential savings from a 3% increase in process efficiency

    ≈$300 Making well-informed decisions earlier, increases efficiency and transforms million* attrition cost to reinvestment opportunities. • Save years of time Per drug, the potential savings from • Optimize resources for the most valuable projects just a 3% increase in process • Gain deeper insights

  7. Slide 7: Eroom's Law

    Eroom’s Law Moore's Law vs Eroom's Law 1E+09 100000000 Eroom’s Law is the observation 30 Transistor # per $1B 10000000 that the cost of developing new NME per $1B 1000000 drugs is increasing exponentially, out pacing the productivity of 100000 drug discovery. The reverse 10000 is Moore's Law, which

  8. Slide 8: Early Development Crucial for Success

    Early Development Crucial for Success • Setting the Stage • Strategy, Timeline, and Financial Planning (Decision Point Map) o Target Product Profile (Decision Guide) - Quantitatively aligning on parameters that are most o Ensure critical requirements are met and important the most appropriate regula

  9. Slide 9: Development is a team sport requiring everyone to pull/push in the same direction

    Development is a team sport requiring everyone to pull/push in the same direction. Illustrative example: Team flexes based on program needs Functional Areas ✓ Program management (dedicated lead) ✓ Clinical pharmacology ✓ Pharmacometrics ✓ Regulatory strategy Team Size ✓ Biostatistics ✓ Market access

  10. Slide 10: Certara's methodologies deliver greater certainty from molecules to market

    Certara’s methodologies are aimed to deliver greater certainty from molecules to market. Design programs Leveraging All Improving Available Data Decision Making Combining deep regulatory insight, Utilizing MIDD to Maximizing scientific rigor, and address questions, information from cross-functional

  11. Slide 11: Commercial Considerations for Early Development – Setting the Destination

    Commercial Considerations for Early Development – Setting the Destination Maximilian Vargas, PhD, MBA Vice President, Evidence & Access Strategy Certara 11

  12. Slide 12: Why Early Clinical Development Matters Commercially

    Why Early Clinical Development Matters Commercially • Drug development isn’t only a scientific journey – it’s a business investment • Commercial thinking should start early, with the end in mind o What does a minimum viable product look like? And an optimal one? o What are the competitive differenti

  13. Slide 13: Value Creation During Development De-risk & Proof of Hope

    Value Creation During Development De-risk & Proof of Hope How biotech valuation grows across phases Phase 1 Phase 2 Phase 3 Phase 4 Market Clinical Trials Clinical Trials Clinical Trials Clinical Trials Launch & Growth Company First human Efficacy FDA/EMA Large trials, FDA valuation trials, safety t

  14. Slide 14: Example target product profile

    TPP Section Minimum Criteria Target Criteria How to De-Risk in Early Dev ? Example target product profile Indication: Approved for slowing Approved for disease Phase II/III Trials Treatment of idiopathic disease progression in IPF modification and Prior knowledge/in silico pulmonary fibrosis (IPF) s

  15. Slide 15: Value Creation in Early Development

    Value Creation in Early Development • TPP Alignment – Probability of Hitting TPP • Proof of developability o Can you create a stable formulation at a reasonable price that will deliver the drug effectively o Acceptable dose and dosing frequency o Early safety and tolerability o Embrace the power of

  16. Slide 16: Translating Phase 1 Data to Competitive Differentiation with MBMA

    Translating Phase 1 Data to Competitive Differentiation with MBMA EXAMPLE Third-generation antisense oligonucleotide targeting PCSK9. In a Phase 1 study, subcutaneous dosing produced >90% suppression within one week, sustained for ~4 weeks, LDL-C levels dropped in a dose-dependent manner. The drug w

  17. Slide 17: Conclusions

    Conclusions • Early clinical decisions shape long-term commercial success — including valuation, access, and differentiation • TPP alignment and stakeholder input must start in Phase I, not wait for later-stage programs • Cross-functional integration (clinical, regulatory, commercial) is essential f

  18. Slide 18: Securing Biotech Investment: Strategies for Success

    Securing Biotech Investment: Strategies for Success Colin Callaghan, BPharm, MBA Senior Director, R&D Program Leadership Certara 18

  19. Slide 19: Factors Driving Investment Attractiveness

    Factors Driving Value Proposition Investment What you have inc. Technology Attractiveness What you intend to do with it What are the advantages What is the Strategy What is the potential return Confidence In Delivery Team Access to resources Innovation Plan Budget 19

  20. Slide 20: A Well-Conceived Strategy Increases Value Potential

    A Well-Conceived Strategy Increases Value Potential Clinical Development: Regulatory: special programs, indication, biomarker, special region(s), PRS population, PIs / KOLs Communication and News DATA Risk Identification and flow: long range view, Mitigation: both internal target best events to (pro

  21. Slide 21: Great! Can You Do It? Increasing Confidence In Delivery

    Great! Can You Do It? Increasing Confidence In Delivery Better data faster? Choosing the right vendors is critical Great plans: • Anticipate Your Team is #1 • Align • Communicate © Copyright 2025 Certara, Inc. All rights reserved. 21

  22. Slide 22: Catalyze your funding efforts with an investor-ready strategy

    Partner with Certara to deliver: Catalyze your 1. A more compelling scientific and business case funding efforts 2. based on medical need and commercial value Strong positioning based on competitive with an investor- 3. landscape and market analysis A development plan/trajectory that leverages ready

  23. Slide 23: Certara's early development program: 3 packages

    Certara’s early development program is provided as a series of 3 packages that are tailored to your in-house expertise/capabilities and program needs 1 Certara does not provide manufacturing or wet lab services but will provide oversight, coordination, and timeline management Stage Supporting Functi

  24. Slide 24: Certara Early Development: Expertise for lead candidate selection through FIH

    Certara Early Development: Expertise, for lead candidate selection through first-in-human (FIH) trial Reduce tactical complexity with a sponsor-side partner that provides flexible, scalable support through a single point of contact Streamlined access to cross-functional expertise High complexity Wit

  25. Slide 25: Questions?

    Questions? Contact us for a complimentary strategy session with one of our experts.

  26. Slide 26: Contact our speakers

    Contact our speakers Kevin Hershberger, BPharm, MBA Colin Callaghan, BPharm, MBA Max Vargas, PhD, MBA Vice President Nonclinical Senior Director, Program Leadership Vice President, Evidence & Access Development Sciences Certara Strategy Certara Certara kevin.hershberger@certara.com colin.callaghan@c

  27. Slide 27: www.certara.com

    www.certara.com 27

Certara — Blueprint for Biotech Success webinar (September 2025) on 6ix